Drug Information

Drug General Information
Drug ID
D01XYJ
Former ID
DAP000701
Drug Name
Zidovudine
Synonyms
AZT; Antiviral; Azidodeoxythymidine; Azidothymidine; Aztec; Retrovir; ZDV; ZVD; Zidovudin; Zidovudina; Zidovudinum; AZT Antiviral; AZT TRANSPLACENTAL CARCINOGENESIS STUDY; Antiviral AZT; Cpd S; Racemic Liposomal AZT; ZIDOVUDINE [AZT]; Zidovudina [Spanish]; Zidovudine EP III; Zidovudinum [Latin]; BW A509U; BWA 509U; BWA509U; K7 [P Ti2 W10 O40]; AZT & EPO; AZT & HPA; AZT & Lymphoblastoid Interferon; AZT & SST; AZT & rsT4; AZT & sCD4; AZT & srCD4; AZT (Antiviral); AZT+PRO 140; AZT, Antiviral; Apo-Zidovudine; BW-A 509U; BW-A509U; BWA-509U; DRG-0004; Intron A & AZT; Novo-Azt; Propolis+AZT; Retrovir (TN); Retrovir(TM); Retrovis (TN); Zidovudine+PRO 140; AZT & Colony-stimulating factor 2; AZT & Concanavalin A (ConA); AZT & GM-CSF; AZT & IFN-alpha; AZT & IL-1; AZT & IL-2; AZT & IL-6; AZT & Li & EPO; AZT & NP (from PHCA or HSA); AZT & PM-19; BW-A-509U; DS-4152 & AZT; Liposomal AZT-SN-1; Liposomal AZT-SN-3; PC-SOD+AZT;RIFN-beta seron & AZT; AZT & CD4(178)-PE 40; AZT & Li & GM-CSF; AZT & Li & IL-1; AZT & Li & IL-6; AZT & rIFN.alpha.2; Racemic-dipalmitoylglycerophospho-AZT (in a lipid vesicle); Zidovudine (JAN/USP/INN); Zidovudine [USAN:INN:BAN:JAN]; AZT & rsCD4 & rIFN.alpha.A; SN-1-dipalmitoylglycerophospho-AZT (in a lipid vesicle); SN-3-dipalmitoylglycerophospho-AZT (in a lipid vesicle); AZT & Interferon-.alpha.-2; Met-SDF-1.beta. & AZT; Met-SDF-1.beta. & Zidovudine; Interferon AD + 3'-azido-3'-deoxythymidine; 1-(3-Azido-2,3-dideoxy-beta-D-ribofuranosyl)thymine; 3′-Azido-3′-deoxythymidine; 3' Azido 2',3' Dideoxythymidine; 3' Azido 3' deoxythymidine; 3'-Azido-2',3'-Dideoxythymidine; 3'-Azido-3'-deoxythymidine; 3'-Azido-3'-deoxythymidine & Concanavalin A; 3'-Azido-3'-deoxythymidine & Erythropoietin; 3'-Azido-3'-deoxythymidine & Heteropolyoxotungstate PM-19; 3'-Azido-3'-deoxythymidine & Interleukin-1; 3'-Azido-3'-deoxythymidine & Interleukin-2; 3'-Azido-3'-deoxythymidine & Interleukin-6; 3'-Azido-3'-deoxythymidine & Lithium & Erythropoietin; 3'-Azido-3'-deoxythymidine & Lithium & Interleukin-1; 3'-Azido-3'-deoxythymidine & Lithium & Interleukin-6; 3'-Azido-3'-deoxythymidine & Lymphoblastoid Interferon; 3'-Azido-3'-deoxythymidine & Sho-Saiko-To; 3'-Azido-3'-deoxythymidine (AIDS); 3'-Azido-3'deoxythymidine & Interferon-alpha; 3'-Azidothymidine; 3'-Deoxy-3'-azidothymidine; 3'-azido-3'-deoxythymidine, AZT; 3-Azido-3-deoxythymidine; ZDV
Drug Type
Small molecular drug
Indication Human immunodeficiency virus infection [ICD9: 279.3; ICD10:B20-B26] Approved [468057], [536361]
Therapeutic Class
Anti-HIV Agents
Company
GlaxoSmithKline
Structure
Download
2D MOL

3D MOL
Formula
C10H13N5O4
InChI
InChI=1S/C10H13N5O4/c1-5-3-15(10(18)12-9(5)17)8-2-6(13-14-11)7(4-16)19-8/h3,6-8,16H,2,4H2,1H3,(H,12,17,18)/t6-,7+,8+/m0/s1
InChIKey
HBOMLICNUCNMMY-XLPZGREQSA-N
CAS Number
CAS 30516-87-1
PubChem Compound ID
35370
PubChem Substance ID
9419, 595886, 596433, 596437, 596594, 596595, 597291, 597292, 597293, 597457, 597458, 597459, 597460, 597461, 597462, 597463, 597555, 597641, 597664, 597665, 600904, 601536, 602048, 622272, 624122, 643735, 644084, 855980, 7846195, 7847479, 7980906, 8149829, 8173993, 11335699, 11360938, 11364242, 11366804, 11369366, 11372752, 11373842, 11377528, 11461910, 11484570, 11488743, 11491322, 11492147, 11495162, 12013681, 12146009, 14799161
SuperDrug ATC ID
J05AF01
SuperDrug CAS ID
cas=030516871
Drug Resistance Mutation (DRM)
DRM DRM Info
Target and Pathway
Target(s) HIV reverse transcriptase Target Info Inhibitor [535958]
References
Ref 468057(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4825).
Ref 536361Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. Epub 2007 Feb 20.
Ref 535958Antiviral drugs in current clinical use. J Clin Virol. 2004 Jun;30(2):115-33.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.